# Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Source: https://onco.cc/trials/nct03069469/  
OnCo record `nct03069469` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Vimseltinib in tenosynovial giant cell tumour, run by Deciphera Pharmaceuticals, LLC, active and no longer recruiting.

## Summary

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor is a phase 1/2 interventional study registered as NCT03069469 by Deciphera Pharmaceuticals, LLC, with 120 participants planned, started 2017-02-16 and due to reach its primary completion in 2028-08. Interventions recorded: Vimseltinib. Conditions listed: Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03069469
- Phase: 1/2
- Setting: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
- Sponsor: Deciphera Pharmaceuticals, LLC
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT03069469: https://clinicaltrials.gov/study/NCT03069469

## Connected records

- cancers: [Tenosynovial giant cell tumour (TGCT)](https://onco.cc/cancers/tenosynovial-giant-cell-tumour/)
- drugs: [Vimseltinib](https://onco.cc/drugs/vimseltinib/)
- companies: [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/)

---
JSON: https://onco.cc/api/v1/entities/nct03069469.json